@kenzzyalexas's Zepbound results claim, fact-checked

What did @kenzzyalexas actually say?

Honestly? Not much that can be fact-checked. The transcript captured by this video is a garbled string of lyrics or noise, not a coherent medical claim. The actual content is the visual "results speak for themselves" framing, the Zepbound name-drop, and the hashtag invitation to "ask me how." That combination is doing real work, even without spoken claims. The implicit message: I took Zepbound, look at me now, come find out more. That is a testimonial structure, and testimonials are among the most potent, and most misleading, formats in health content.

The hashtag #caloriedeficitgirls at least nods toward behavioral change alongside the drug, which is worth noting. Tirzepatide, the active ingredient in Zepbound, is not a magic button. The clinical trials were run alongside lifestyle intervention. Crediting the drug alone without mentioning that context leaves viewers with an incomplete picture.

Does the science back this up?

Zepbound's weight loss results are genuinely impressive by drug trial standards, but the full picture is more complicated than a before-and-after framing suggests. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants on 15mg tirzepatide lost a mean of 20.9% of body weight over 72 weeks. That is a real, significant number. But dropout rates, side effect burden, and what happens when people stop taking the drug all matter too.

A follow-up study (Aronne et al., 2024, JAMA) found that patients who discontinued tirzepatide after losing weight regained roughly two-thirds of it within a year. The drug works while you take it. That is not a small caveat. It means the "results" in any testimonial video are, in many cases, temporary unless the person continues on the medication indefinitely or has made substantial lifestyle changes that hold independently. Viewers cheering on a transformation need to understand that stopping the drug often reverses it.

What did they get wrong (or right)?

There is nothing technically wrong said here, because nothing specific was said. But the framing gets a few things wrong by omission. First, no mention of side effects. Gastrointestinal events, including nausea, vomiting, and diarrhea, affected the majority of participants in SURMOUNT-1. These are not rare edge cases. Second, no mention of cost or access. Zepbound listed around $1,060 per month at launch without insurance, and coverage remains inconsistent.

What they got right, at least partially: the hashtag reference to calorie deficit suggests some awareness that the drug is not operating in isolation. Tirzepatide works partly by suppressing appetite, which mechanistically supports a calorie deficit. So that pairing is not wrong, it just needed more explanation to be useful rather than decorative. Giving partial credit where it is due, the creator did not make outrageous or fabricated claims. The problem is the claims they did not make.

What should you actually know?

Tirzepatide is a dual GIP and GLP-1 receptor agonist, which is a different mechanism than semaglutide-only drugs like Ozempic or Wegovy. That distinction matters. Wilding et al. (2021, NEJM) showed semaglutide produced roughly 14.9% mean weight loss in STEP 1. Tirzepatide outperformed that in head-to-head adjacent comparisons, though no direct RCT has compared them head-to-head in the same trial as of early 2025.

If you are considering Zepbound based on content like this, the relevant questions are: do you meet the clinical criteria (BMI over 30, or over 27 with a weight-related comorbidity), can you access it consistently, and have you discussed cardiovascular history with a prescriber? The FDA approved tirzepatide for chronic weight management in 2023. It is a regulated medication, not a supplement, and it requires a legitimate clinical relationship to obtain legally. Anyone offering it without that context is operating outside appropriate medical standards.

• Tirzepatide showed up to 20.9% mean body weight loss in SURMOUNT-1 at the highest dose (Jastreboff et al., 2022, NEJM).
• Weight regain after stopping is well-documented and averages around two-thirds of lost weight within 12 months (Aronne et al., 2024, JAMA).
• Common side effects include nausea, diarrhea, and vomiting, affecting the majority of patients at some point during treatment.
• Zepbound requires a prescription and is not equivalent to compounded tirzepatide products, which vary in formulation and lack the same regulatory oversight.